Physician profile
Andre Dwayne Miller
NPI 1922413913
$1,432.13
in general payments reported to CMS, 2019-2025
18 companies · $671 in 2025
The $671 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.81 · 2020: $49.40 · 2021: $99.71 · 2022: $94.81 · 2023: $35.97 · 2024: $463 · 2025: $671.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,170.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $517.05 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Axsome Therapeutics, INC. | $124.20 | 2025 | Auvelity |
| Novo Nordisk INC | $121.14 | 2024-2025 | Wegovy, Ozempic |
| Lilly USA, LLC | $95.71 | 2022-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $85.43 | 2022-2025 | Trelegy Ellipta, Arexvy |
| Pfizer INC. | $83.64 | 2025 | |
| Exact Sciences Corporation | $62.56 | 2024-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $58.79 | 2024-2025 | |
| Amgen INC. | $52.42 | 2020-2021 | |
| Abbvie INC. | $40.65 | 2024 | |
| Genentech USA, INC. | $39.36 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $30.77 | 2021-2023 | Seglentis |
| Novartis Pharmaceuticals Corporation | $29.51 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $25.01 | 2022 | |
| Lundbeck LLC | $20.56 | 2024 | Rexulti |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $19.34 | 2021 | |
| Phathom Pharmaceuticals, INC. | $13.70 | 2024 | Voquezna |
| Boston Scientific Corporation | $12.29 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andre Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.